ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06436157 (Genetic Testing Uptake Through an Enhanced Oncology Nurse-Led Intervention in Patients With Solid Tumors), which is not on this map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetic Testing Uptake Through an Enhanced Oncology Nurse-Led Intervention in Patients With Solid Tumors (GENESIS): A Pilot Study
Who cites it
74 citing papers in PubMed, 109 citations in OpenAlex.
- Randomized trial promoting cancer genetic risk assessment when genetic counseling cost removed: 1-year follow-up.JNCI cancer spectrum · 2024Trial
- Cascade Genetic Risk Education and Testing in Families With Hereditary Cancer Syndromes: A Pilot Study.JCO oncology practice · 2023Trial
- Development and feasibility testing of a conversational chatbot supporting genetic education and testing for hereditary cancer.Journal of community genetics · 2026Article
- Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Communication With Clinicians and Relatives About Cascade Genetic Testing in Cancer Patients With Germline Pathogenic Variants.JCO precision oncology · 2026Article
- Evaluating a Mendelian Risk Prediction Model That Aggregates Across Genes and Cancers.Genetic epidemiology · 2026Article
- Breast cancer surgery in the era of genetic uncertainty: real-world outcomes in BRCA1/2 pathogenic variants and variants of uncertain significance.BMC cancer · 2026Article
- Landscape of germline genetic alterations among non-western young male patients with cancer. Findings from The Jordanian exploratory cancer genetics study.Frontiers in oncology · 2026Article
- Review
- Article
- Article
- Double heterozygous germline pathogenic variants in patients referred to a tertiary cancer genetics clinic in Singapore.Frontiers in oncology · 2026Article
- Characterization of Copy Number Variants in Hereditary Cancer Patients Through NGS Shows a Distinctive PALB2 Contribution to the Diagnostic Yield.Human mutation · 2026Article
- Homologous Recombination Deficiency and Survival in Ovarian High-Grade Serous Carcinoma by Self-Reported Race.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Patient characteristics, treatment patterns, and clinical outcomes in HER2-negative early breast cancer by germline BRCA status.Future oncology (London, England) · 2025Observational
- Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.Breast cancer research and treatment · 2025Observational
- Women's Intention to Participate in Predictive Breast Cancer Genetic Testing: A Cross-Sectional Survey of in Iran.Health science reports · 2025Article
- Genetic counseling referral rates and genetic testing outcomes in women with young breast cancer: a 20-year Canadian review.Breast cancer research and treatment · 2025Article
- Deciphering the Overlapping Immune Mechanism Between Depression and Breast Cancer.International journal of molecular sciences · 2025Article
- Characterizing trends in clinical genetic testing: A single-center analysis of EHR data from 1.8 million patients over two decades.American journal of human genetics · 2025Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
purposeGenetic testing is important for breast and ovarian cancer risk reduction and treatment, yet little is known about its evolving use.
methodsSEER records of women of age ≥ 20 years diagnosed with breast or ovarian cancer from 2013 to 2017 in California or Georgia were linked to the results of clinical germline testing through 2019. We measured testing trends, rates of variants of uncertain significance (VUS), and pathogenic variants (PVs).
resultsOne quarter (25.2%) of 187,535 patients with breast cancer and one third (34.3%) of 14,689 patients with ovarian cancer were tested; annually, testing increased by 2%, whereas the number of genes tested increased by 28%. The prevalence of test results by gene category for breast cancer cases in 2017 were
conclusionA testing gap persists for patients with ovarian cancer (34.3% tested
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.